Regeneron's VEGF Trap Misses in NSCLC; Focus Stays on AMD
By Jennifer Boggs
Monday, March 14, 2011
Anti-angiogenic drug aflibercept (VEGF-Trap) failed to improve overall survival in a Phase III trial in non-small-cell lung cancer, news that came as no surprise to analysts who have criticized Regeneron Pharmaceuticals Inc.'s and partner Paris-based Sanofi-Aventis SA's aggressive move into late-stage trials.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.